Literature DB >> 2788520

Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1.

H Loppnow1, P Libby.   

Abstract

We investigated the regulation of IL6 biological activity, de novo synthesis, and mRNA levels in adult vascular endothelial cells (EC) by bacterial endotoxin or inflammatory cytokines. Cells incubated without stimulus released scant IL6 activity. IFN gamma, IL2, or PDGF did not augment IL6 release from EC. LPS, lipid A, and TNF increased IL6 release modestly (5 to 20-fold), while recombinant IL1s (rIL1s) stimulated this process 100 to 400-fold. Differential release of IL6 from EC treated with LPS or rIL1 continued for at least 144 hr. Exposure to LPS or rIL1 caused EC to synthesize IL6 de novo. EC secreted the newly synthesized IL6 into the supernatant, rather than retaining it within or bound to cells. EC accumulated IL6 mRNA after 3 hr of exposure to rIL1. However, we could only detect IL6 message in cells incubated with LPS under "superinduction" conditions with cycloheximide, consistent with lower levels of IL6 biological activity in response to LPS compared to IL1 stimulation. We propose that local production of IL6 by vascular EC, which comprise the barrier between tissues and the blood, may influence regional immune and inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788520     DOI: 10.1016/0008-8749(89)90095-6

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  37 in total

Review 1.  The biology of endotoxin.

Authors:  H Heine; E T Rietschel; A J Ulmer
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

2.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

3.  Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14.

Authors:  H Loppnow; F Stelter; U Schönbeck; C Schlüter; M Ernst; C Schütt; H D Flad
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

4.  Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis.

Authors:  Alexander G Bick; James P Pirruccello; Gabriel K Griffin; Namrata Gupta; Stacey Gabriel; Danish Saleheen; Peter Libby; Sekar Kathiresan; Pradeep Natarajan
Journal:  Circulation       Date:  2019-11-11       Impact factor: 29.690

5.  Platelet-activating factor stimulates interleukin-6 production by human endothelial cells and synergizes with tumor necrosis factor for enhanced production of granulocyte-macrophage colony stimulating factor.

Authors:  C Lacasse; S Turcotte; D Gingras; J Stankova; M Rola-Pleszczynski
Journal:  Inflammation       Date:  1997-04       Impact factor: 4.092

6.  Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6.

Authors:  H Loppnow; P Libby
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

7.  Binding of lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human cells is mediated by soluble CD14 and LPS-binding protein.

Authors:  J Schletter; H Brade; L Brade; C Krüger; H Loppnow; S Kusumoto; E T Rietschel; H D Flad; A J Ulmer
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

Review 8.  The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin.

Authors:  R R Schumann; E T Rietschel; H Loppnow
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

9.  Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.

Authors:  M Z Mazlam; H J Hodgson
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

10.  Anti-CD14 antibodies reduce responses of cultured human endothelial cells to endotoxin.

Authors:  E J von Asmuth; M A Dentener; V Bazil; M G Bouma; J F Leeuwenberg; W A Buurman
Journal:  Immunology       Date:  1993-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.